Compare EHang Holdings Ltd - ADR (EH) vs Mesoblast Limited (MESO) Price & Performance

EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical outlook and mixed financials. Revenue declined to $418M in 2025 with a net loss of $276M, though gross margins remain strong at 61.5%. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a cautious sentiment.

The outlook is challenged by persistent losses and regulatory scrutiny, but the company's cash position of $1.12B provides some buffer. Investment opportunities lie in the nascent eVTOL market, while risks include execution missteps and intense competition. Analyst consensus is divided, reflecting high uncertainty.

MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.

The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.